BACKGROUND: In vitro studies indicate that the Fy blood group system antigens serve as receptors for chemokines such as monocyte chemotactic protein-1 (MCP-1) and RANTES. However, it is unclear whether subjects with the Fy(a-b-) phenotype exhibit altered clearance and hence altered plasma levels of chemo-kines, because they still express Fy on endothelial cells. STUDY DESIGN AND METHODS: To clarify a possible in vivo role of Fy on RBCs in the regulation of chemo-kine levels, healthy young volunteers of common Fy phenotypes were compared in a cross-sectional study. RESULTS: More than 90 percent of the 34 subjects of African origin were Fy(a-b-), one black volunteer was Fy(a+b-), and two were Fy(a-b+). As expected, all 65 white volunteers were positive for either Fy(a) and/or Fy(b). Unexpectedly, persons expressing either Fy(a) and/or Fy(b) had significantly higher plasma levels of MCP-1 than Fy(a-b-) volunteers (women: 154 vs. 110 ng/L, p<0.01; men: 179 vs. 169 ng/L, p = 0.03). Surprisingly, plasma levels of MCP-1 were found to be sex-dependent: median MCP-1 levels averaged 180 ng per L in men but only 139 ng per L in women (p<0.001). Further, MCP-1 levels decreased significantly throughout the menstrual cycle of 18 women studied longitudinally. CONCLUSION: MCP-1 levels are about 30 percent higher in men than in premenopausal women, and MCP-1 levels are also higher in persons with RBCs expressing Fy antigens than in Fy(a-b-) persons. These findings have direct implications for the concept and interpretation of clinical studies measuring MCP-1 levels; the role of the observed differences in MCP-1 levels for the pathogenesis of MCP-1-dependent diseases, such as atherosclerosis, merits further investigation.
BACKGROUND: In vitro studies indicate that the Fy blood group system antigens serve as receptors for chemokines such as monocyte chemotactic protein-1 (MCP-1) and RANTES. However, it is unclear whether subjects with the Fy(a-b-) phenotype exhibit altered clearance and hence altered plasma levels of chemo-kines, because they still express Fy on endothelial cells. STUDY DESIGN AND METHODS: To clarify a possible in vivo role of Fy on RBCs in the regulation of chemo-kine levels, healthy young volunteers of common Fy phenotypes were compared in a cross-sectional study. RESULTS: More than 90 percent of the 34 subjects of African origin were Fy(a-b-), one black volunteer was Fy(a+b-), and two were Fy(a-b+). As expected, all 65 white volunteers were positive for either Fy(a) and/or Fy(b). Unexpectedly, persons expressing either Fy(a) and/or Fy(b) had significantly higher plasma levels of MCP-1 than Fy(a-b-) volunteers (women: 154 vs. 110 ng/L, p<0.01; men: 179 vs. 169 ng/L, p = 0.03). Surprisingly, plasma levels of MCP-1 were found to be sex-dependent: median MCP-1 levels averaged 180 ng per L in men but only 139 ng per L in women (p<0.001). Further, MCP-1 levels decreased significantly throughout the menstrual cycle of 18 women studied longitudinally. CONCLUSION:MCP-1 levels are about 30 percent higher in men than in premenopausal women, and MCP-1 levels are also higher in persons with RBCs expressing Fy antigens than in Fy(a-b-) persons. These findings have direct implications for the concept and interpretation of clinical studies measuring MCP-1 levels; the role of the observed differences in MCP-1 levels for the pathogenesis of MCP-1-dependent diseases, such as atherosclerosis, merits further investigation.
Authors: Dusten Unruh; Ramprasad Srinivasan; Tyler Benson; Stephen Haigh; Danielle Coyle; Neil Batra; Ryan Keil; Robert Sturm; Victor Blanco; Mary Palascak; Robert S Franco; Wilson Tong; Tapan Chatterjee; David Y Hui; W Sean Davidson; Bruce J Aronow; Theodosia Kalfa; David Manka; Abigail Peairs; Andra Blomkalns; David J Fulton; Julia E Brittain; Neal L Weintraub; Vladimir Y Bogdanov Journal: Circulation Date: 2015-10-14 Impact factor: 29.690
Authors: Hemant Kulkarni; Vincent C Marconi; Weijing He; Michael L Landrum; Jason F Okulicz; Judith Delmar; Dickran Kazandjian; John Castiblanco; Seema S Ahuja; Edwina J Wright; Robin A Weiss; Robert A Clark; Matthew J Dolan; Sunil K Ahuja Journal: Blood Date: 2009-07-20 Impact factor: 22.113
Authors: Weijing He; Stuart Neil; Hemant Kulkarni; Edward Wright; Brian K Agan; Vincent C Marconi; Matthew J Dolan; Robin A Weiss; Sunil K Ahuja Journal: Cell Host Microbe Date: 2008-07-17 Impact factor: 21.023
Authors: Monika Pruenster; Liesbeth Mudde; Paula Bombosi; Svetla Dimitrova; Marion Zsak; Jim Middleton; Ann Richmond; Gerard J Graham; Stephan Segerer; Robert J B Nibbs; Antal Rot Journal: Nat Immunol Date: 2008-12-07 Impact factor: 25.606
Authors: Francoise Bachelerie; Adit Ben-Baruch; Amanda M Burkhardt; Christophe Combadiere; Joshua M Farber; Gerard J Graham; Richard Horuk; Alexander Hovard Sparre-Ulrich; Massimo Locati; Andrew D Luster; Alberto Mantovani; Kouji Matsushima; Philip M Murphy; Robert Nibbs; Hisayuki Nomiyama; Christine A Power; Amanda E I Proudfoot; Mette M Rosenkilde; Antal Rot; Silvano Sozzani; Marcus Thelen; Osamu Yoshie; Albert Zlotnik Journal: Pharmacol Rev Date: 2013-11-11 Impact factor: 25.468